Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.46 |
| ▸ | KDR | P35968 | 14/20 | 0.46 |
| ▸ | AXL | P30530 | 3/20 | 0.45 |
| ▸ | MET | P08581 | 3/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22505650 | 0.88 | PDGFRA (0.56) | PDGFRAKDRAXLMETMERTK | |
| SCHEMBL22505636 | 0.88 | PDGFRA (0.48) | PDGFRAKDR | |
| SCHEMBL22505586 | 0.88 | AXL (0.60) | PDGFRAKDRAXLMETMERTK | |
| SCHEMBL22505750 | 0.87 | FLT3 (0.58) | PDGFRAKDRAXLMET | |
| SCHEMBL22505612 | 0.83 | PDGFRA (0.51) | PDGFRAKDRAXLMET | |
| SCHEMBL22505745 | 0.83 | KDR (0.57) | PDGFRAKDRAXLMET | |
| SCHEMBL22535127 | 0.81 | PDGFRA (0.47) | PDGFRAKDR | |
| SCHEMBL22505729 | 0.79 | PDGFRA (0.53) | PDGFRAKDRAXLMETMERTK | |
| SCHEMBL22505655 | 0.77 | KDR (0.49) | PDGFRAKDRAXLMET | |
| SCHEMBL22505751 | 0.77 | KDR (0.50) | PDGFRAKDRAXLMETIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800741-B2 | Quinoline compound, preparation method and medical use therefor | WEE2, WEE1, HASPIN | PDGFRA 2993/4885KDR 2448/4885AXL 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.